Customer Publication

Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1) cell line

Authors: Z. Szász et al.

Journal: Biomedicine & Pharmacotherapy (2024)

Research Areas: Cancer research

Cell Lines: PANC-1, COLO-205, A2058 and EBC-1 (Pancreatic adenocarcinoma cell, colorectal adenocarcinoma cells, metastatic melanoma cells, lung squamous cell carcinoma cells)

Summary: Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive and lethal cancer. To improve treatment options, researchers tried to find and optimise peptide-based drug conjugates with daunorubicin (Dau) as the cytotoxic antitumour agent. The results showed the modification in position six with chlorination (Conj16) is the most effective on the pancreas adenocarcinoma cell line (PANC-1) and induce cellular senescence in the short term and subsequent apoptotic cell death. Furthermore, the cardiotoxic effect of Dau was markedly reduced in the form of peptide conjugates. In conclusion, Conj16 had the most effective antitumor activity on PANC-1 cells, which makes this conjugate promising for developing new targeted therapies without cardiotoxic effects. HoloMonitor was used to study the morphology change with conjugate treatment, including cells' average area, optical thickness and optical volume.

Keywords: HoloMonitor M4, cell morphology, targeted tumour therapy, targeting peptide, pancreatic adenocarcinoma, daunorubicin, cellular senescenceno, cardiotoxicity

Read the article …